Similarly, CHK1 inhibition was found to augment the effect of nucleoside analog fludarabine in incurable chronic lymphocytic leukemia irrespective of TP53 status [21, 35]. This evidence concerns the gene TP53 and B-cell chronic lymphocytic leukemia.